Clinical and serologic data were collected, including antibody specificity for proteinase 3 (PR3-ANCA) and myeloperoxidase (MPO-ANCA), as well as the temporal relationship to SARS-CoV-2 infection or COVID-19 vaccination.<h4>Results</h4>A significant increase in AAV incidence was observed during the pandemic, rising from 22.4 cases per million in 2019 to 37.9 cases per million in 2021 (<i>p</i> = 0.031). This evidence concerns the gene PRTN3 and COVID-19.